- Home
- ELWS vs PHGE Comparison
ELWS vs PHGE Comparison
Compare ELWS & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- PHGE
- Stock Information
- Founded
- ELWS 2018
- PHGE 2015
- Country
- ELWS Japan
- PHGE Israel
- Employees
- ELWS N/A
- PHGE N/A
- Industry
- ELWS
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- PHGE Health Care
- Exchange
- ELWS Nasdaq
- PHGE Nasdaq
- Market Cap
- ELWS 12.1M
- PHGE 12.6M
- IPO Year
- ELWS 2023
- PHGE N/A
- Fundamental
- Price
- ELWS $3.19
- PHGE $0.58
- Analyst Decision
- ELWS
- PHGE Strong Buy
- Analyst Count
- ELWS 0
- PHGE 1
- Target Price
- ELWS N/A
- PHGE $15.00
- AVG Volume (30 Days)
- ELWS 182.1K
- PHGE 344.1K
- Earning Date
- ELWS 09-30-2025
- PHGE 11-13-2025
- Dividend Yield
- ELWS N/A
- PHGE N/A
- EPS Growth
- ELWS N/A
- PHGE N/A
- EPS
- ELWS N/A
- PHGE N/A
- Revenue
- ELWS $3,083,071.00
- PHGE N/A
- Revenue This Year
- ELWS N/A
- PHGE N/A
- Revenue Next Year
- ELWS N/A
- PHGE N/A
- P/E Ratio
- ELWS N/A
- PHGE N/A
- Revenue Growth
- ELWS 145.52
- PHGE N/A
- 52 Week Low
- ELWS $1.64
- PHGE $0.34
- 52 Week High
- ELWS $10.50
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- ELWS 56.54
- PHGE 58.47
- Support Level
- ELWS $2.60
- PHGE $0.50
- Resistance Level
- ELWS $3.40
- PHGE $0.60
- Average True Range (ATR)
- ELWS 0.32
- PHGE 0.03
- MACD
- ELWS 0.09
- PHGE 0.01
- Stochastic Oscillator
- ELWS 66.13
- PHGE 70.84
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).